There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyadic International (DYAI – Research Report), Biophytis (BPTS – Research Report) and 2seventy bio (TSVT – Research Report) with bullish sentiments.
Dyadic International (DYAI)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Dyadic International today and set a price target of $6.00. The company’s shares closed last Thursday at $1.86.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
Dyadic International has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
See today’s best-performing stocks on TipRanks >>
Biophytis (BPTS)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biophytis today and set a price target of $15.00. The company’s shares closed last Thursday at $0.71, close to its 52-week low of $0.35.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biophytis with a $15.00 average price target.
2seventy bio (TSVT)
Morgan Stanley analyst Matthew Harrison maintained a Buy rating on 2seventy bio yesterday and set a price target of $28.00. The company’s shares closed last Thursday at $13.99.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on 2seventy bio is a Strong Buy with an average price target of $29.50, representing an 117.7% upside. In a report issued on January 20, Goldman Sachs also maintained a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DYAI:
- Dyadic to Participate in Two Upcoming Investor Conferences
- Dyadic announces initiation of dosing of Phase 1 trial of DYAI-100
- Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
- Dyadic International sells equity interest in Alphazyme for $1.27M
- Dyadic Announces Sale of Equity Interest in Alphazyme
